Patents by Inventor Bryan Irving

Bryan Irving has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11859010
    Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
    Type: Grant
    Filed: September 7, 2022
    Date of Patent: January 2, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
  • Publication number: 20230322922
    Abstract: Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.
    Type: Application
    Filed: December 10, 2022
    Publication date: October 12, 2023
    Inventors: Volker SCHELLENBERGER, Eric JOHANSEN, Angela HENKENSIEFKEN, Darragh MACCANN, James MCCLORY, Philipp KUHN, Andre FRENZEL, Milton TO, Michael FOX, Bryan IRVING, Mika DERYNCK
  • Publication number: 20230287127
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2023
    Publication date: September 14, 2023
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Publication number: 20230265146
    Abstract: The present invention relates to compositions comprising biologically active proteins, such as cytokines, linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of related disorders and conditions.
    Type: Application
    Filed: December 2, 2022
    Publication date: August 24, 2023
    Inventors: Volker SCHELLENBERGER, Eric JOHANSEN, Angela HENKENSIEFKEN, Bryan IRVING, Tracy YOUNG, Vibha CHAUHAN, Valentine YEUNG
  • Publication number: 20230050083
    Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
    Type: Application
    Filed: September 7, 2022
    Publication date: February 16, 2023
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Leila Marie BOUSTANY, Sherry L. LA PORTE, Bryan A. IRVING, Jeanne Grace FLANDEZ
  • Publication number: 20220362378
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: February 14, 2022
    Publication date: November 17, 2022
    Inventors: Heather MAECKER, Bryan IRVING
  • Patent number: 11472889
    Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 18, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
  • Publication number: 20210340253
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Publication number: 20210332132
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Publication number: 20210032345
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: April 21, 2020
    Publication date: February 4, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Publication number: 20200399366
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: March 13, 2020
    Publication date: December 24, 2020
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • Patent number: 10646567
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Publication number: 20190135943
    Abstract: Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Leila Marie Boustany, Sherry L. La Porte, Bryan A. Irving, Jeanne Grace Flandez
  • Publication number: 20190016807
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2018
    Publication date: January 17, 2019
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Publication number: 20180236066
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING
  • Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Patent number: 9895441
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Heather Maecker, Bryan Irving
  • Publication number: 20180021431
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING